Inhibikase Therapeutics (IKT) Registration Filing summary

Company overview and business model

• Clinical-stage pharmaceutical company focused on developing therapeutics for cardiopulmonary diseases, primarily Pulmonary Arterial Hypertension (PAH), an orphan indication.

• Lead product candidate IKT-001 is a prodrug of imatinib mesylate, designed to improve GI tolerance and target disease-modifying pathways in PAH.

• Completed non-human primate safety studies and a bioequivalence clinical trial in healthy volunteers; cleared to initiate a Phase 2b trial in PAH in September 2024.

• Holds commercialization rights and patent protection for IKT-001 in the U.S. until 2033, with potential extension to 2045.

• Acquired CorHepta Pharmaceuticals in February 2025 to expand the product pipeline.

Financial performance and metrics

• As of March 31, 2025, had 74,341,540 shares of common stock outstanding.

• Net tangible book value as of March 31, 2025, was $85.7 million, or $1.15 per share.

• After a $200 million offering at $1.70 per share, as adjusted net tangible book value would be $291 million, or $1.52 per share.

• Immediate dilution to new investors estimated at $0.18 per share.

Use of proceeds and capital allocation

• Proceeds intended for general corporate purposes, including clinical trials, product development and manufacturing for IKT-001 and other candidates, R&D, acquisitions, working capital, and capital expenditures.

• Management retains broad discretion over allocation and timing of proceeds.